Efficacy and safety of upadacitinib after 4 years of treatment in patients with moderately to severely active ulcerative colitis: interim long-term data from the phase 3 open-label extension study (U-ACTIVATE)

被引：0
|
作者：
Panaccione, R. [1 ]
Lichtenstein, G. [2 ]
Colombel, J. F. [3 ]
Nakase, H. [4 ]
Yao, X. [5 ]
Klaff, J. [5 ]
Kujawski, M. [5 ]
Rizzo, L.
Suravaram, S.
Vermeire, S. [6 ]
机构：
[1] Univ Calgary, Div Gastroenterol & Hepatol, Calgary, AB, Canada
[2] Univ Penn, Div Gastroenterol & Hepatol, Sch Med, Philadelphia, PA USA
[3] Icahn Sch Med Mt Sinai, Henry Janowitz Div Gastroenterol, New York, NY USA
[4] Sapporo Med Univ, Dept Gastroenterol & Hepatol, Sch Med, Sapporo, Japan
[5] AbbVie Inc, Gastroenterol, N Chicago, IL USA
[6] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.0041
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP002
引用
收藏
页码：i80 / i82
页数：3
相关论文
共 50 条
  • [1] Efficacy and Safety of Upadacitinib After 3 Years of Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Long-Term Data From the Phase 3 Open-Label Extension Study (U-ACTIVATE)
    Panaccione, Remo
    Higgins, Peter
    Nakase, Hiroshi
    Glover, Sarah C.
    Danese, Silvio
    Colombel, Jean-Frederic
    Eccleston, Jason
    Kujawski, Michelle
    Remple, Valencia
    Yao, Xuan
    Suravaram, Smitha
    Schreiber, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10): : S1061 - S1062
  • [2] Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)
    Panaccione, R.
    Lichtenstein, G.
    Nakase, H.
    Armuzzi, A.
    Kucharzik, T.
    Levy, G.
    Palac, H.
    Kujawski, M.
    Klaff, J.
    Cheon, J. H.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 644 - 646
  • [3] SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: LONG-TERM DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)
    Panaccione, Remo
    Lichtenstein, Gary R.
    Nakase, Hiroshi
    Armuzzi, Alessandro
    Kucharzik, Torsten
    Levy, Gweneth
    Palac, Hannah
    Kujawski, Michelle
    Klaff, Justin
    Cheon, Jae Hee
    GASTROENTEROLOGY, 2023, 164 (06) : S1100 - S1100
  • [4] Efficacy and safety of retreatment with upadacitinib after treatment interruption in ulcerative colitis: Data from the phase 3 open-label extension study U-ACTIVATE
    Panaccione, R.
    Colombel, J. F.
    Dubinsky, M.
    Hisamatsu, T.
    Remple, V.
    Garrison, A.
    Klaff, J.
    Kujawski, M.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1812 - I1813
  • [5] Efficacy and safety of retreatment with upadacitinib after treatment interruption in ulcerative colitis: Data from the phase 3 open-label extension study U-ACTIVATE
    Panaccione, Remo
    Colombel, Jean-Frederic
    Dubinsky, Marla
    Hisamatsu, Tadakazu
    Remple, Valencia
    Garrison, Andrew
    Klaff, Justin
    Kujawski, Michelle R.
    Baraty, Brandon
    Vermeire, Severine
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 165 - 165
  • [6] Corticosteroid-Free Remission Through 3 Years of Upadacitinib Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 Long-Term Extension Study U-ACTIVATE
    Dubinsky, Marla
    Atreya, Raja
    Nakase, Hiroshi
    Kujawski, Michelle
    Crooks, James
    Cheng, Erica
    Klaff, Justin
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S764 - S764
  • [7] LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
    Abreu, Maria T.
    Danese, Silvio
    Wolf, Douglas C.
    Canavan, James B.
    Jain, Anjali
    Wu, Hsiuanlin
    Petersen, AnnKatrin
    Charles, Lorna
    Afzali, Anita
    Panaccione, Remo
    GASTROENTEROLOGY, 2023, 164 (06) : S208 - S208
  • [8] Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
    Panaccione, R.
    Danese, S.
    Wolf, D. C.
    Canavan, J. B.
    Jain, A.
    Wu, H.
    Petersen, A.
    Charles, L.
    Afzali, A.
    Abreu, M. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 534 - 534
  • [9] Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension
    Siegel, C.
    Danese, S.
    Rubin, D. T.
    Sabino, J.
    Long, M. D.
    Cross, R. K.
    Armuzzi, A.
    Blumenstein, I.
    Kobayashi, T.
    Lama, S.
    Charles, L.
    Cetin, V.
    Petersen, A.
    Wu, H.
    Wang, D.
    Jain, A.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I100 - I101
  • [10] Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study
    Feagan, Brian G.
    Matsuoka, Katsuyoshi
    Rogler, Gerhard
    Laharie, David
    Vermeire, Severine
    Danese, Silvio
    Loftus Jr, Edward V.
    Beales, Ian
    Schreiber, Stefan
    Kim, Hyo Jong
    Faes, Margaux
    de Haas, Angela
    Masior, Tomasz
    Rudolph, Christine
    Peyrin-Biroulet, Laurent
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (05) : 563 - 584
12345